A new peptide inhibitor has also been developed to decrease Drp1 interaction with ATAD3A suppressing mitochondrial fragmentation and mtDNA damage, as well as reducing HD neuropathology (Zhao et al., 2019). This evidence concerns the gene DNM1L and Huntington disease.